Skip to content

Author

P. Andrau

We have 1 of 10 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Persistence, Safety and Pharmacokinetics of Vedolizumab After Switching to the Subcutaneous Route in a Prospective French National Cohort Study.

The persistence at 1 year from switch to SC-VDZ in IBD patients was 84%, and Vedolizumab drug levels were similar between persistent and non-persistent patients throughout the study period.

Marianne Hupé, Nicolas Mathieu, A. Amiot et al. · 2 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.